Document is current
Any future updates will be listed below
-
Authors
Yildirim, Hilin
Widdershoven, Christiaan V
Aarts, Maureen JB
Bex, Axel
Bloemendal, Haiko J
Bochove-Overgaauw, Deirdre M
Hamberg, Paul
Herbschleb, Karin H
van der Hulle, Tom
Lagerveld, Brunolf W
van Oijen, Martijn GH
Oosting, Sjoukje F
van Thienen, Johannes V
van der Veldt, Astrid AM
Westgeest, Hans M
Zeijdner, Evelijn E
Aben, Katja KH
van den Hurk, Corina
Zondervan, Patricia J
Bins, Adriaan D
- License Information
-
More Information
Article History
Received: 19 January 2023
Accepted: 21 June 2023
First Online: 11 July 2023
Declarations
:
: This multicenter study received approval by the medical ethical review board of the Amsterdam University Medical Center, The Netherlands in 2022 (2021_218). All TwiCs to be conducted within this infrastructure will require separate approval from a medical ethical review committee / institutional review board. All methods will be conducted in accordance with the ethical standards of the declaration of Helsinki and will be in accordance with relevant guidelines and regulations. Informed consent will be obtained from all patients before inclusion.
: All scientific output and developments concerning PRO-RCC will be publicly available through the project website (ExternalRef removed). The Dutch PRO-RCC newsletter is open for registration to all patients, clinicians, and researchers who express interest in subscribing.
: Not applicable.
: SFO reports research grants from Novartis and Celldex Therapeutics, and consultancy fees from Bristol Myers Squibb (all paid to the institution) outside the submitted work. HMW reports personal fees from Ipsen, Astellas and Roche outside the submitted work. Other authors have no competing interests to declare.
